The updated guidelines from the American Diabetes Association and the statement from the American College of Cardiology strongly recommend GLP-1 RA use for patients with T2D who already have or are at high risk for cardiovascular disease.2,6 The results of this study suggest that GLP-1 RA and similar agents have not yet been adopted as a strategy for broader cardiovascular risk reduction. Here, GLP1R is linked to diabetes mellitus.